| Title |
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, October 2012
|
| DOI | 10.2147/ndt.s36771 |
| Pubmed ID | |
| Authors |
Zsolt Mezei, Daniel Bereczki, Lilla Racz, Laszlo Csiba, Tünde Csepany |
| Abstract |
Decreased relapse rate and slower disease progression have been reported with long-term use of immunomodulatory treatments (IMTs, interferon beta or glatiramer acetate) in relapsing-remitting multiple sclerosis. There are, however, patients who do not respond to such treatments, and they can be potential candidates for alternative therapeutic approaches. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 5% |
| Unknown | 18 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 26% |
| Other | 3 | 16% |
| Student > Master | 2 | 11% |
| Professor | 2 | 11% |
| Researcher | 2 | 11% |
| Other | 2 | 11% |
| Unknown | 3 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 37% |
| Psychology | 2 | 11% |
| Nursing and Health Professions | 1 | 5% |
| Agricultural and Biological Sciences | 1 | 5% |
| Neuroscience | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 6 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2012.
All research outputs
#3,372,527
of 25,584,565 outputs
Outputs from Neuropsychiatric Disease and Treatment
#459
of 3,120 outputs
Outputs of similar age
#23,876
of 191,340 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#3
of 14 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,120 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 191,340 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.